Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: Requirements depend on target organ

Blood

Volumn 105, Issue 5, 2005, Pages 2227-2234

  Anderson, Britt E ^a   McNiff, Jennifer M ^a   Jain, Dhanpat ^a   Blazar, Bruce R ^a   Shlomchik, Warren D ^a   Shlomchik, Mark J ^b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Box 208035   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD86 ANTIGEN; CD86 PROTEIN, MOUSE; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; MOUSE; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; TARGET ORGAN; ALLOTRANSPLANTATION; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC DISEASE; DISEASE MODEL; ENTEROPATHY; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; SKIN DISEASE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; INTESTINAL DISEASES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; ORGAN SPECIFICITY; SKIN DISEASES; TRANSPLANTATION, HOMOLOGOUS;

EID: 14944370670     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-08-3032     Document Type: Article

References (56)

1. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100:406-414.
2. Anderson D, DeFor T, Burns L, et al. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections. Biol Blood Marrow Transplant. 2003;9:52-59.
3. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75:2459-2464.
4. Castagna L, Bertuzzi A, Nozza A. et al. Reduced intensity conditioning regimen followed by glyco-sylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas. Bone Marrow Transplant. 2002;30:207-214.
5. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: longterm follow-up of a randomized trial. Blood. 2002; 100:415-419.
6. Remberger M, Kumlien G, Aschan J, et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:674-682.
7. Zecca M, Prete A, Rondelli R, et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood. 2002; 100:1192-1200.
8. Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, et al. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood. 2002;99:1442-1448.
9. Clark FJ, Freeman L, Dzionek A, et al. Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease. Transplantation. 2003;75:221-225.
10. Imamura M, Tsutsumi Y, Miura Y, Toubai T, Tanaka J. Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation. Hematology. 2003;8:19-26.
11. Nachbaur D, Kircher B, Eisendle K, Latzer K, Haun M, Gastl G. Phenotype, function and chimaerism of monocyte-derived blood dendritic cells after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2003;123:119-126.
12. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415.
13. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.
14. Hamilton BL. L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens. J Immunol. 1987;139:2511-2515.
15. Germain RN. MHC-dependent antigen process ing and peptide presentation: providing ligands for T lymphocyte activation. Cell. 1994;76:287-299.
16. Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr Opin Immunol. 1996;8:348-354.
17. Sant AJ. Endogenous antigen presentation by MHC class II molecules. Immunol Res. 1994;13: 253-267.
18. Wolf PR, Ploegh HL. How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Dev Biol. 1995;11:267-306.
19. Brooks AG, McCluskey J. Class Il-restricted presentation of a hen egg lysozyme determinant derived from endogenous antigen sequestered in the cytoplasm or endoplasmic reticulum of the antigen presenting cells. J Immunol. 1993;150: 3690-3697.
20. Bogen B, Weiss S. Processing and presentation of idiotypes to MHC-restricted T cells. Int Rev Immunol. 1993;10:337-355.
21. Bodmer H, Viville S, Benoist C, Mathis D. Diversity of endogenous epitopes bound to MHC class II molecules limited by invariant chain. Science. 1994;263:1284-1286.
22. Lechler R, Aichinger G, Lightstone L. The endogenous pathway of MHC class II antigen presentation. Immunol Rev. 1996;151:51-79.
23. Li J, Helm K, Howell CD. Contributions of donor CD4 and CD8 cells to liver injury during murine graft-versus-host disease. Transplantation. 1996; 62:1621-1628.
24. Nonomura A, Kono N. Mizukami Y, Nakanuma Y. Histological changes of the liver in experimental graft-versus-host disease across minor histocompatibility barriers, VII: a light and electron microscopic study of the large bile duct. Liver. 1993;13: 163-171.
25. Vierling JM, Ruderman WB, Jaffee BD, Fennell RH Jr. Claman HN. Hepatic lesions in murine chronic graft-versus-host disease to minor histocompatibility antigens: a reproducible model of nonsuppurative destructive cholangitis. Transplantation. 1989;48:717-718.
26. McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol. 1999;163:5693-5699.
27. Borriello F. Sethna MP, Boyd SD, et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity, 1997;6:303-313.
28. + T cells that survive irradiation regulate chronic graft-versus-host disease. Blood. 2004;104: 1565-1573.
29. + T cells do not induce graft-versus-host disease. J Clin Invest. 2003;112:101-108.
30. + T cells in the periphery and secondary proliterative responses elicited upon peptide challenge. J Immunol. 1999;163:232-241.
31. Merad M, Hoffmann P, Ranheim E, et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med. 2004;10: 510-517.
32. + immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000;12:431-440.
33. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19:225-252.
34. + T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol. 1997;158:29-39.
35. Korngold R, Sprent J. Lethal GVHD across minor histocompatibility barriers: nature of the effector cells and role of the H-2 complex. Immunol Rev. 1983;71:5-29.
36. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med. 2002;8:575-581.
37. Duffner UA, Maeda Y, Cooke KR, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004;172: 7393-7398.
38. Carbone FR, Bevan MJ. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med. 1990;171:377-387.
39. + T cell-mediated graft-versus-host disease model. J Clin Invest. 2003;112:1880-1886.
40. Green JM, Noel PJ, Sperling AI, et al. Absence of B7-dependent responses in CD28-deficient mice. Immunity. 1994;1:501-508.
41. Sperling AI, Auger JA, Ehst BD, Rulifson IC, Thompson CB, Bluestone JA. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J Immunol. 1996;157:3909-3917.
42. Schweitzer AN, Sharpe AH. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production. J Immunol. 1998;161:2762-2771.
43. Chen BJ, Cui X, Sempowski GD, Liu C, Chao NJ. Transfer of allogeneic CD62L - memory T cells without graft-versus-host disease. Blood. 2004; 103:1534-1541.
44. Lumsden JM, Prasad SJ, Peach RJ, Ronchese F. The effects of B7-dependent costimulation on T cell division and survival in vivo and in vitro are dependent on antigen concentration. Eur J Immunol. 2003;33:2074-2082.
45. Speiser DE, Bachmann MF, Shahinian A, Mak TW, Ohashi PS. Acute graft-versus-host disease without costimulation via CD28. Transplantation. 1997;63:1042-1044.
46. Yu XZ, Martin PJ, Anasetti C. Role of CD28 in acute graft-versus-host disease. Blood. 1998;92: 2963-2970.
47. Via CS, Rus V, Nguyen P, Linsley P, Gause WC. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. J Immunol. 1996;157:4258-4267.
48. + T cells. J Immunol. 1996;157:3250-3259.
49. Blazar BR, Taylor PA, Linsley PS, Vallera DA. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood. 1994;83: 3815-3825.
50. Blazar BR, Taylor PA, Gray GS, Vallera DA. The role of T cell subsets in regulating the in vivo efficacy of CTLA4-Ig in preventing graft-versus-host disease in recipients of fully MHC or multiple minor histocompatibility- disparate donor inocula. Transplantation. 1994;58:1422-1426.
51. Inaba K, Inaba M, Witmer-Pack M, Hatchcock K, Hodes R, Steinman RM. Expression of B7 co stimulator molecules on mouse dendritic cells. Adv Exp Med Biol. 1995;378:65-70.
52. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180:1263-1272.
53. + T-helper and a T-killer cell. Nature. 1998; 393:474-478.
54. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80: 2964-2968.
55. Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc. 1993;25:1216-1217.
56. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL Nat Med. 2004;10:987-992.